{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:03:36Z","timestamp":1770908616358,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40123-025-01301-0","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:14:05Z","timestamp":1768547645000},"page":"591-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Budget Impact of Faricimab in Neovascular Age-Related Macular Degeneration in the Netherlands: A Systematic Review and Meta-Analysis of Injection Count"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-7976","authenticated-orcid":false,"given":"Mohamed","family":"El Alili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine J.","family":"van de Laar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen P. F.","family":"de Greeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes G. F.","family":"Vromans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freekje","family":"van Asten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith E.","family":"Bosmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"10153","key":"1301_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147\u201359.","journal-title":"Lancet"},{"key":"1301_CR2","doi-asserted-by":"publisher","first-page":"1486168","DOI":"10.3389\/fpubh.2024.1486168","volume":"12","author":"Y Huang","year":"2024","unstructured":"Huang Y, Tang T, Wang D, Gao Y, Zhang M. Global, regional, and national burden of age-related macular degeneration, 1990\u20132019: an age-period-cohort analysis based on the Global Burden of Disease 2019 Study. Front Public Health. 2024;12:1486168.","journal-title":"Front Public Health"},{"key":"1301_CR3","doi-asserted-by":"publisher","first-page":"1138428","DOI":"10.3389\/fpubh.2023.1138428","volume":"11","author":"B Jiang","year":"2023","unstructured":"Jiang B, Jiang C, Li J, Lu P. Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: results from the global burden of disease study 2019. Front Public Health. 2023;11:1138428.","journal-title":"Front Public Health"},{"key":"1301_CR4","doi-asserted-by":"crossref","unstructured":"Koning-Backus APM, Jong JCK, Rooij JGJ, et al. Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design. Nutrients. 2023;15(3):602.","DOI":"10.3390\/nu15030602"},{"issue":"2","key":"1301_CR5","first-page":"327","volume":"263","author":"SW Quist","year":"2025","unstructured":"Quist SW, Nab H, Postma M, Amarakoon S, van Asten F, Freriks R. A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands. Graefes Arch Clin Exp Ophthalmol. 2025;263(2):327\u201345.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"1301_CR6","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of age-related macular degeneration in Europe the past and the future. Ophthalmology. 2017;124(12):1753\u201363.","journal-title":"Ophthalmology"},{"key":"1301_CR7","unstructured":"VWS. Dutch Ministry of Public Health and Healthcare Waiting Times. 2025. https:\/\/www.vzinfo.nl\/wachttijden\/ziekenhuiszorg\/polikliniek. Accessed  2025 May\u00a014."},{"key":"1301_CR8","unstructured":"RIVM. StatLine - Costs of Illness 2019. https:\/\/statline.rivm.nl\/#\/RIVM\/nl\/dataset\/50091NED\/table?ts=1747210296148. Accessed  2025 May\u00a014."},{"issue":"1","key":"1301_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001967","volume":"10","author":"DT Wong","year":"2025","unstructured":"Wong DT, Aboobaker S, Maberley D, Sharma S, Yoganathan P. Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations. BMJ Open Ophthalmol. 2025;10(1):e001967.","journal-title":"BMJ Open Ophthalmol"},{"key":"1301_CR10","unstructured":"Lechanteur Y, Hecke M van. Standpunt Faricimab 2024. 2024. https:\/\/www.oogheelkunde.org\/wp-content\/uploads\/2024\/04\/standpunt-faricimab-definitief-15072024.pdf. Accessed  2025 May\u00a013."},{"key":"1301_CR11","unstructured":"FMS. Leeftijdsgebonden Maculadegeneratie (LMD) - Richtlijn - Richtlijnendatabase. 2025. https:\/\/richtlijnendatabase.nl\/richtlijn\/leeftijdsgebonden_maculadegeneratie_lmd\/startpagina_-_leeftijdsgebonden_maculadegeneratie_lmd.html. Accessed  2025 May\u00a013."},{"key":"1301_CR12","unstructured":"Santeon. Richtlijn \u2018medicamenteuze behandeling van leeftijdsgebonden maculadegeneratie en diabetisch macula-oedeem.\u2019 2025."},{"issue":"7","key":"1301_CR13","first-page":"2118","volume":"65","author":"H Mhmud","year":"2024","unstructured":"Mhmud H, Tigchelaar-Besling OM, Vermeulen J, et al. Long term outcomes for neovascular age-related macular degeneration in a frugal country: the Netherlands. Invest Ophthalmol Vis Sci. 2024;65(7):2118\u20132118.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"1301_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/aos.16777","volume":"103","author":"M Scheffer","year":"2025","unstructured":"Scheffer M, Menting J, Rausch-Koster P, van Nispen R, van Dulmen S. Looking beyond the eyes of the patient: the importance of effective communication in the treatment of age-related macular degeneration. Acta Ophthalmol. 2025;103(2):205\u201314.","journal-title":"Acta Ophthalmol"},{"issue":"0","key":"1301_CR15","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12(0):2483\u201391.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"1301_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE two-year results from the phase\u00a03 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year\u00a02. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"issue":"10326","key":"1301_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Ruiz CQ, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16\u00a0weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase\u00a03, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"key":"1301_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17506","author":"ETS Butler","year":"2025","unstructured":"Butler ETS, Arnold-Vangsted A, Schou MG, et al. Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: a systematic review with network meta-analysis. Acta Ophthalmol. 2025. https:\/\/doi.org\/10.1111\/aos.17506.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"1301_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100744","volume":"5","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP. Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a scoping review. Ophthalmol Sci. 2025;5(4):100744.","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"1301_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00417-021-05359-x","volume":"260","author":"SW Quist","year":"2022","unstructured":"Quist SW, de Jong LA, van Asten F, Knoester P, Postma MJ, Freriks RD. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022;260(4):1083\u201395.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1301_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-022-02151-x","volume":"37","author":"KYC Teo","year":"2023","unstructured":"Teo KYC. Real-world evidence for neovascular age-related macular degeneration: a practical approach. Eye. 2023;37(1):1\u20133.","journal-title":"Eye"},{"key":"1301_CR22","first-page":"1","volume":"14","author":"A Khodor","year":"2025","unstructured":"Khodor A, Caranfa JT, Nanda T, et al. Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis. Ophthalmol Ther. 2025;14:1\u201320.","journal-title":"Ophthalmol Ther"},{"key":"1301_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1301_CR24","unstructured":"Google. NotebookLM. 2025. https:\/\/notebooklm.google.com\/. Accessed  2025 Jul 17."},{"issue":"2","key":"1301_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41433-024-03481-8","volume":"39","author":"QA Dihan","year":"2025","unstructured":"Dihan QA, Nihalani BR, Tooley AA, Elhusseiny AM. Eyes on Google\u2019s NotebookLM: using generative AI to create ophthalmology podcasts with a single click. Eye. 2025;39(2):215\u20136.","journal-title":"Eye"},{"issue":"8","key":"1301_CR26","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41433-025-03817-y","volume":"39","author":"M Reuter","year":"2025","unstructured":"Reuter M, Philippone M, Benton B, Dilley L. Generative AI in clinical practice: novel qualitative evidence of risk and responsible use of Google\u2019s NotebookLM. Eye. 2025;39(8):1650\u20132.","journal-title":"Eye"},{"issue":"1","key":"1301_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13643-024-02682-2","volume":"13","author":"L Ge","year":"2024","unstructured":"Ge L, Agrawal R, Singer M, et al. Leveraging artificial intelligence to enhance systematic reviews in health research: advanced tools and challenges. Syst Rev. 2024;13(1):269.","journal-title":"Syst Rev"},{"issue":"3","key":"1301_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.11124\/JBIES-23-00268","volume":"22","author":"TH Barker","year":"2024","unstructured":"Barker TH, Habibi N, Aromataris E, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024;22(3):378\u201388.","journal-title":"JBI Evid Synth"},{"key":"1301_CR29","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i03","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice\u202f: multivariate imputation by chained equations in R. J Stat Softw. 2011. https:\/\/doi.org\/10.18637\/jss.v045.i03.","journal-title":"J Stat Softw"},{"key":"1301_CR30","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw"},{"key":"1301_CR31","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). 2024. www.cochrane.org\/handbook. Accessed 2025 Jul 23."},{"issue":"1","key":"1301_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"1301_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1301_CR34","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"1301_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/00031305.2012.687494","volume":"66","author":"JMV Hoef","year":"2012","unstructured":"Hoef JMV. Who invented the delta method? Am Stat. 2012;66(2):124\u20137.","journal-title":"Am Stat"},{"issue":"4","key":"1301_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med"},{"issue":"3","key":"1301_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/biomet\/63.3.581","volume":"63","author":"DB Rubin","year":"1976","unstructured":"Rubin DB. Inference and missing data. Biometrika. 1976;63(3):581.","journal-title":"Biometrika"},{"issue":"1","key":"1301_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/stan.12023","volume":"68","author":"G Vink","year":"2014","unstructured":"Vink G, Frank LE, Pannekoek J, van Buuren S. Predictive mean matching imputation of semicontinuous variables. Stat Neerlandica. 2014;68(1):61\u201390.","journal-title":"Stat Neerlandica"},{"issue":"4","key":"1301_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1207\/s15327906mbr3304_5","volume":"33","author":"JL Schafer","year":"1998","unstructured":"Schafer JL, Olsen MK. Multiple imputation for multivariate missing-data problems: a data analyst\u2019s perspective. Multivar Behav Res. 1998;33(4):545\u201371.","journal-title":"Multivar Behav Res"},{"key":"1301_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","volume":"110","author":"P Madley-Dowd","year":"2019","unstructured":"Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63\u201373.","journal-title":"J Clin Epidemiol"},{"issue":"20","key":"1301_CR41","doi-asserted-by":"publisher","first-page":"11699","DOI":"10.1002\/ece3.6806","volume":"10","author":"S Kambach","year":"2020","unstructured":"Kambach S, Bruelheide H, Gerstner K, Gurevitch J, Beckmann M, Seppelt R. Consequences of multiple imputation of missing standard deviations and sample sizes in meta-analysis. Ecol Evol. 2020;10(20):11699\u2013712.","journal-title":"Ecol Evol"},{"key":"1301_CR42","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). 2024. www.cochrane.org\/handbook. Accessed 23 Jul 2025."},{"key":"1301_CR43","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE working group. 2013. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed 24 Oct 2025."},{"key":"1301_CR44","unstructured":"Z-index. List prices July 2025 [internal data]. 2025."},{"key":"1301_CR45","unstructured":"NZa. Open data van de Nederlandse Zorgautoriteit. 2025. https:\/\/opendisdata.nza.nl\/?zorgproduct=079799020. Accessed 24 Oct 2025."},{"key":"1301_CR46","unstructured":"ZIN. Zinnige Zorg - Verbetersignalement Leeftijdsgebonden maculadegeneratie. 2021. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2021\/09\/14\/zinnige-zorg-verbetersignalement-maculadegeneratie. Accessed  2025 Jul 28."},{"key":"1301_CR47","unstructured":"CBS. Statline - Population; gender, age and marital status on January 1st. 2024. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/7461BEV\/table. Accessed  2025 Jul 28."},{"issue":"6","key":"1301_CR48","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1111\/aos.14712","volume":"99","author":"FD Verbraak","year":"2021","unstructured":"Verbraak FD, Ponsioen DL, Tigchelaar-Besling OAM, et al. Real-world treatment outcomes of neovascular age-related macular degeneration in the Netherlands. Acta Ophthalmol. 2021;99(6):e884\u201392.","journal-title":"Acta Ophthalmol"},{"key":"1301_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040470","author":"W Aljundi","year":"2024","unstructured":"Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD. First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16040470.","journal-title":"Pharmaceutics"},{"key":"1301_CR50","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/IAE.0000000000004322","volume":"45","author":"NR Ambati","year":"2025","unstructured":"Ambati NR, Leone A, Brill D, Sisk RA. Real-world long-term outcomes of intravitreal faricimab in previously treated chronic neovascular age-related macular degeneration. Retina. 2025;45:446\u201353.","journal-title":"Retina"},{"key":"1301_CR51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12886-025-03953-9","volume":"25","author":"MA Bantounou","year":"2025","unstructured":"Bantounou MA, Elsheikh M, Ijasan A, Santiago C. Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series. BMC Ophthalmol. 2025;25:117.","journal-title":"BMC Ophthalmol"},{"key":"1301_CR52","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond). 2024;38:3569\u201377.","journal-title":"Eye (Lond)"},{"key":"1301_CR53","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, et al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Ther. 2024;13:2985\u201397.","journal-title":"Ophthalmol Ther"},{"key":"1301_CR54","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Hernaez JS, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond). 2024;38:3059\u201364.","journal-title":"Eye (Lond)"},{"issue":"9","key":"1301_CR55","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.oret.2025.03.015","volume":"9","author":"G Grimaldi","year":"2025","unstructured":"Grimaldi G, Ambresin A, Pfister IB, et al. One-year outcomes after switching to faricimab in eyes with pretreated neovascular age-related macular degeneration: a Swiss retina research network report. Ophthalmol Retina. 2025;9(9):838\u201347.","journal-title":"Ophthalmol Retina"},{"key":"1301_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00669-2","volume":"11","author":"M Hafner","year":"2025","unstructured":"Hafner M, Eckardt F, Siedlecki J, et al. Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab. Int J Retina Vitreous. 2025;11:44.","journal-title":"Int J Retina Vitreous"},{"key":"1301_CR57","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.2147\/OPTH.S494605","volume":"18","author":"A Hang","year":"2024","unstructured":"Hang A, Ngo T, Virk JS, et al. Intravitreal faricimab for previously treated neovascular age-related macular degeneration. Clin Ophthalmol. 2024;18:3781\u20139.","journal-title":"Clin Ophthalmol"},{"key":"1301_CR58","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","volume":"67","author":"T Hikichi","year":"2023","unstructured":"Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"1301_CR59","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41433-025-03616-5","volume":"39","author":"IK Janmohamed","year":"2025","unstructured":"Janmohamed IK, Mushtaq A, Kabbani J, et al. 1-year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration. Eye (Lond). 2025;39:1344\u20138.","journal-title":"Eye (Lond)"},{"key":"1301_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1301_CR61","doi-asserted-by":"publisher","DOI":"10.1177\/24741264241271649","author":"A Khodor","year":"2024","unstructured":"Khodor A, Choi S, Nanda T, et al. Visual and anatomic responses in patients with neovascular age-related macular degeneration and a suboptimal response to anti-VEGF therapy switched to faricimab. J Vitreoretin Dis. 2024. https:\/\/doi.org\/10.1177\/24741264241271649.","journal-title":"J Vitreoretin Dis"},{"key":"1301_CR62","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"key":"1301_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/life14020193","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Kumar NA, et al. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life. 2024. https:\/\/doi.org\/10.3390\/life14020193.","journal-title":"Life"},{"key":"1301_CR64","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8583348","volume":"2024","author":"SV Savant","year":"2024","unstructured":"Savant SV, Kwan JT, Barouch F, et al. Durability and efficacy of faricimab in treatment-resistant retinal edema utilizing \u201creal-world\u201d dosing regimens. J Ophthalmol. 2024;2024:8583348.","journal-title":"J Ophthalmol"},{"key":"1301_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","volume":"9","author":"SY Sim","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, et al. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2025;9:22\u201330.","journal-title":"Ophthalmol Retina"},{"key":"1301_CR66","volume":"16","author":"D Sutter","year":"2024","unstructured":"Sutter D, Anderson A, Wheatley S, Sheth V. Quantifying fluid and function in suboptimal responders switched from an anti-vascular endothelial growth factor (VEGF) to faricimab. Cureus. 2024;16:e56652.","journal-title":"Cureus"},{"key":"1301_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato A, Mohan N, Talcott KE, et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol Retina. 2024;8:10\u20137.","journal-title":"Ophthalmol Retina"},{"key":"1301_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17506","author":"ETS Butler","year":"2025","unstructured":"Butler ETS, Arnold-Vangsted A, Schou MG, et al. Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: a systematic review with network meta-analysis. Acta Ophthalmol. 2025. https:\/\/doi.org\/10.1111\/aos.17506.","journal-title":"Acta Ophthalmol"},{"key":"1301_CR69","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40123-025-01098-y","volume":"14","author":"P Wojciechowski","year":"2025","unstructured":"Wojciechowski P, Wdowiak M, Panek M, et al. Efficacy, safety, and injection frequency with novel aflibercept 8\u00a0mg in neovascular age-related macular degeneration: a comparison with existing anti-VEGF regimens using a Bayesian network meta-analysis. Ophthalmol Ther. 2025;14:733\u201353.","journal-title":"Ophthalmol Ther"},{"key":"1301_CR70","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","volume":"13","author":"E Giancipoli","year":"2024","unstructured":"Giancipoli E, Guglielmi A, Bux AV, et al. Real-world outcomes of a loading phase with intravitreal faricimab in neovascular age-related macular degeneration (n-AMD) and diabetic macular edema (DME). Ophthalmol Ther. 2024;13:2163\u201384.","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01301-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:02:45Z","timestamp":1770904965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01301-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Mohamed El Alili, Celine J. van de Laar, Jeroen P.F. de Greeff, and Johannes G.F. Vromans are employees and shareholders of Roche. Freekje van Asten and Judith E. Bosmans report no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}